Observational prospective cohort study on fluid infusion rate and cisplatin-associated complications
Anita Zeneli Research nurse, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Oriana Nanni Director, biostatistic and clinical trials unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Elisa Carretta Biostatistician, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Lorenzo Cecconetto Oncologist, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Rosanna Tedaldi Head nurse, day hospital units of Forlì and Meldola, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Serena Maltoni Infusion nurse, meldola day hospital unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Ivana Barlati Director of nursing and technical service, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Dino Amadori Scientific director, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Anita Zeneli and colleagues present the results of research to investigate the links between chemotherapy duration time and events such as renal toxicity
Aim To evaluate the influence of hydration infusion rate on frequency of systemic complications during chemotherapy administration and intercycle follow up.
Method A prospective study of 101 adult cancer patients undergoing outpatient treatment was conducted. They received 145 cisplatin-based chemotherapy infusions. Cisplatin infusion rate was standard, while fluid infusion rate varied, according to chemotherapy schemas. Infusions were categorised using quartiles of the infusion times distributed into four categories.
Results Clinical response measured by renal output during infusion follow up was registered highest in the shortest duration category (P=0.0230). Anaemia during infusion and at intercycle follow up was associated with infusion duration (P=0.0007; P=0.0136). Renal and myelotoxicity were not statistically associated with infusion duration.
Conclusion The category of shortest infusion duration was the safest. Infusion times of fluid therapy may influence systemic complications during chemotherapy administration and intercycle follow up, and the risk of systemic events may increase in infusions lasting more than five hours. Infusion nurses should take this finding into consideration during care planning.
Cancer Nursing Practice.
12, 10, 34-39.
doi: 10.7748/cnp2013.12.12.10.34.e1026
Correspondence
a.zeneli@irst.emr.it
Peer review
This article has been subject to double blind peer review
Conflict of interest
None declared
Received: 09 September 2013
Accepted: 14 October 2013
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
